Drug-associated	drug-associated	O	O	O	O
acute-onset	acute-onset	O	O	O	O
vanishing	vanishing	O	O	OTHERS	I
bile	bile	O	O	OTHERS	I
duct	duct	O	O	OTHERS	I
and	and	O	O	O	O
Stevens-Johnson	stevens-johnson	O	O	O	O
syndromes	syndromes	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
child	child	O	O	O	O
.	.	O	O	O	O

Acute	acute	O	O	O	O
vanishing	vanishing	O	O	OTHERS	I
bile	bile	O	O	OTHERS	I
duct	duct	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
rare	rare	O	O	O	O
but	but	O	O	O	O
established	established	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
progressive	progressive	O	O	O	O
cholestasis	cholestasis	O	DISEASE	OTHERS	I
in	in	O	O	O	O
adults	adults	O	O	O	O
,	,	O	O	O	O
is	is	O	O	O	O
most	most	O	O	O	O
often	often	O	O	O	O
drug	drug	O	O	O	O
or	or	O	O	O	O
toxin	toxin	O	O	O	O
related	related	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
is	is	O	O	O	O
of	of	O	O	O	O
unknown	unknown	O	O	O	O
pathogenesis	pathogenesis	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
has	has	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
previously	previously	O	O	O	O
in	in	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

Stevens-Johnson	stevens-johnson	O	O	O	O
syndrome	syndrome	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
well-recognized	well-recognized	O	O	O	O
immune	immune	O	O	O	O
complex-mediated	complex-mediated	O	O	O	O
hypersensitivity	hypersensitivity	O	DISEASE	OTHERS	I
reaction	reaction	O	O	O	O
that	that	O	O	O	O
affects	affects	O	O	O	O
all	all	O	O	O	O
age	age	O	O	O	O
groups	groups	O	O	O	O
,	,	O	O	O	O
is	is	O	O	O	O
drug	drug	O	O	O	O
or	or	O	O	O	O
infection	infection	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
has	has	O	O	O	O
classic	classic	O	O	O	O
systemic	systemic	O	O	O	O
,	,	O	O	O	O
mucosal	mucosal	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
dermatologic	dermatologic	O	O	O	O
manifestations	manifestations	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
previously	previously	O	O	O	O
healthy	healthy	O	O	O	O
child	child	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
acute	acute	O	O	O	O
,	,	O	O	O	O
severe	severe	O	O	O	O
,	,	O	O	O	O
rapidly	rapidly	O	O	O	O
progressive	progressive	O	O	O	O
vanishing	vanishing	O	O	OTHERS	I
bile	bile	O	O	OTHERS	I
duct	duct	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
shortly	shortly	O	O	O	O
after	after	O	O	O	O
Stevens-Johnson	stevens-johnson	O	O	O	O
syndrome	syndrome	O	O	O	O
is	is	O	O	O	O
described	described	O	O	O	O
;	;	O	O	O	O
this	this	O	O	O	O
was	was	O	O	O	O
temporally	temporally	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
ibuprofen	ibuprofen	CHEMICALS	O	OTHERS	I
use	use	O	O	O	O
.	.	O	O	O	O

Despite	despite	O	O	O	O
therapy	therapy	O	O	O	O
with	with	O	O	O	O
ursodeoxycholic	ursodeoxycholic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
prednisone	prednisone	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
then	then	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
her	her	O	O	O	O
cholestatic	cholestatic	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
was	was	O	O	O	O
unrelenting	unrelenting	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
cirrhosis	cirrhosis	O	DISEASE	OTHERS	I
shown	shown	O	O	O	O
by	by	O	O	O	O
biopsy	biopsy	O	O	O	O
6	6	O	O	O	O
months	months	O	O	O	O
after	after	O	O	O	O
presentation	presentation	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
case	case	O	O	O	O
documents	documents	O	O	O	O
acute	acute	O	O	O	O
drug-related	drug-related	O	O	O	O
vanishing	vanishing	O	O	OTHERS	I
bile	bile	O	O	OTHERS	I
duct	duct	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
pediatric	pediatric	O	O	O	O
age	age	O	O	O	O
group	group	O	O	O	O
and	and	O	O	O	O
suggests	suggests	O	O	O	O
shared	shared	O	O	O	O
immune	immune	O	O	O	O
mechanisms	mechanisms	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pathogenesis	pathogenesis	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
Stevens-Johnson	stevens-johnson	O	O	O	O
syndrome	syndrome	O	O	O	O
and	and	O	O	O	O
vanishing	vanishing	O	O	OTHERS	I
bile	bile	O	O	OTHERS	I
duct	duct	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
.	.	O	O	O	O

